PMID- 30835559
OWN - NLM
STAT- MEDLINE
DCOM- 20191211
LR  - 20191217
IS  - 1651-2006 (Electronic)
IS  - 1401-7431 (Linking)
VI  - 53
IP  - 2
DP  - 2019 Apr
TI  - Prognostic efficacy of C-reactive protein/albumin ratio in ST elevation 
      myocardial infarction.
PG  - 83-90
LID - 10.1080/14017431.2019.1590628 [doi]
AB  - OBJECTIVE: Although the prognostic efficacy of C-reactive protein (mg/L) and 
      albumin levels (g/L) has been previously associated with poor prognosis in ST 
      elevation myocardial infarction (STEMI), to the best of our knowledge, the 
      prognostic efficacy of C-reactive protein/Albumin ratio (CAR) (mg/g) has not been 
      investigated yet. Thus, this study aimed to investigate the potential efficacy of 
      the CAR in predicting prognosis in STEMI patients. METHOD: We conducted a 
      detailed investigation of 2437 patients with first STEMI treated with a primary 
      percutaneous coronary intervention. After evaluation regarding to exclusion 
      criteria, 2243 patients were found to be eligible for analysis. The mean 
      follow-up of the study was 34 +/- 15 months. RESULTS: The median CAR value of the 
      study population was 2.70 (range: 1.44-4.76), and the patients were divided into 
      three tertiles according to their CAR values. Kaplan-Meier survival analysis 
      showed significantly lower in-hospital and long-term survival rates for the 
      patients in a high CAR tertile. In addition, the CAR was found to be an 
      independent predictor of all-cause mortality (Hazards ratio: 1.033, 95% 
      Confidence Interval: 1.007-1.061, p = .033), and the prognostic performance of 
      the CAR was superior to that of C-reactive protein, albumin, and neutrophil to 
      lymphocyte ratio in the receiver operating characteristic curve comparison. 
      CONCLUSION: The CAR, a newly introduced inflammation-based risk index, was found 
      to be a potentially useful prognostic tool for predicting a poor prognosis in 
      STEMI patients. However, this finding needs to be validated in the future 
      prospective studies.
FAU - Cinar, Tufan
AU  - Cinar T
AUID- ORCID: 0000-0001-8188-5020
AD  - a Department of Cardiology , Health Sciences University, Sultan Abdulhamid Han 
      Training and Research Hospital , Istanbul , Turkey.
FAU - Cagdas, Metin
AU  - Cagdas M
AUID- ORCID: 0000-0001-6704-9886
AD  - b Department of Cardiology , Kafkas University Medical Faculty , Kars , Turkey.
FAU - Rencuzogullari, Ibrahim
AU  - Rencuzogullari I
AUID- ORCID: 0000-0002-0070-9197
AD  - b Department of Cardiology , Kafkas University Medical Faculty , Kars , Turkey.
FAU - Karakoyun, Suleyman
AU  - Karakoyun S
AD  - b Department of Cardiology , Kafkas University Medical Faculty , Kars , Turkey.
FAU - Karabag, Yavuz
AU  - Karabag Y
AUID- ORCID: 0000-0002-8156-315X
AD  - b Department of Cardiology , Kafkas University Medical Faculty , Kars , Turkey.
FAU - Yesin, Mahmut
AU  - Yesin M
AD  - c Department of Cardiology , Kars Harakani State Hospital , Kars , Turkey.
FAU - Sadioglu Cagdas, Oznur
AU  - Sadioglu Cagdas O
AD  - d Department of Internal Medicine , Kafkas University Medical Faculty , Kars , 
      Turkey.
FAU - Tanboga, Halil Ibrahim
AU  - Tanboga HI
AD  - e Department of Cardiology , Ataturk University Medical School , Erzurum , 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20190403
PL  - England
TA  - Scand Cardiovasc J
JT  - Scandinavian cardiovascular journal : SCJ
JID - 9708377
RN  - 0 (ALB protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - C-Reactive Protein/*analysis
MH  - *Decision Support Techniques
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention/adverse effects/mortality
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - ST Elevation Myocardial Infarction/*blood/diagnosis/mortality/*therapy
MH  - Serum Albumin, Human/*analysis
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - C-reactive protein to Albumin ratio
OT  - ST elevation myocardial infarction
OT  - all-cause mortality
EDAT- 2019/03/06 06:00
MHDA- 2019/12/18 06:00
CRDT- 2019/03/06 06:00
PHST- 2019/03/06 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/03/06 06:00 [entrez]
AID - 10.1080/14017431.2019.1590628 [doi]
PST - ppublish
SO  - Scand Cardiovasc J. 2019 Apr;53(2):83-90. doi: 10.1080/14017431.2019.1590628. 
      Epub 2019 Apr 3.